John A Hangasky
Overview
Explore the profile of John A Hangasky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
371
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider E, Hangasky J, Ashley G, Santi D
J Med Chem
. 2025 Feb;
68(3):2301-2306.
PMID: 39895561
This perspective describes the current status and future prospects of developing long- to ultralong-acting anti-obesity peptides. First, we discuss the current status of lipidation, PEGylation, and Fc fusion technologies to...
2.
Leveraging long-acting IL-15 agonists for intratumoral delivery and enhanced antimetastatic activity
Hangasky J, Fernandez R, Stellas D, Hails G, Karaliota S, Ashley G, et al.
Front Immunol
. 2024 Nov;
15:1458145.
PMID: 39559362
Introduction: IL-15 agonists hold promise as immunotherapeutics due to their ability to induce the proliferation and expansion of cytotoxic immune cells including natural killer (NK) and CD8 T cells. However,...
3.
Schneider E, Hangasky J, Fernandez R, Ashley G, Santi D
Proc Natl Acad Sci U S A
. 2024 Nov;
121(47):e2415815121.
PMID: 39531496
The objective of this work was to develop a long-acting form of the lipidated peptide semaglutide that can be administered to humans once-monthly. Semaglutide was attached to hydrogel microspheres by...
4.
Henise J, Hangasky J, Charych D, Carreras C, Ashley G, Santi D
Sci Rep
. 2024 Jun;
14(1):14000.
PMID: 38890412
Intratumoral (IT) therapy is a powerful method of controlling tumor growth, but a major unsolved problem is the rapidity that injected drugs exit tumors, limiting on-target exposure and efficacy. We...
5.
Hangasky J, Chen W, Dubois S, Daenthanasanmak A, Muller J, Reid R, et al.
J Immunother Cancer
. 2022 Feb;
10(1).
PMID: 35101947
Background: Interleukin-15 (IL-15) is an important cytokine necessary for proliferation and maintenance of natural killer (NK) and CD8 T cells, and with great promise as an immuno-oncology therapeutic. However, IL-15...
6.
Hangasky J, Waldmann T, Santi D
Front Immunol
. 2020 Sep;
11:1813.
PMID: 32903632
Interleukin-15 (IL-15) is crucial for the proliferation and survival of NK and CD8 T memory cells, and of significant interest in immuno-oncology. Immune cell expansion requires continuous IL-15 exposure above...
7.
Thompson M, Blake-Hedges J, Pereira J, Hangasky J, Belcher M, Moore W, et al.
Nat Commun
. 2020 Jun;
11(1):2931.
PMID: 32523014
Despite intensive study, plant lysine catabolism beyond the 2-oxoadipate (2OA) intermediate remains unvalidated. Recently we described a missing step in the D-lysine catabolism of Pseudomonas putida in which 2OA is...
8.
Nyein H, Bariya M, Kivimaki L, Uusitalo S, Liaw T, Jansson E, et al.
Sci Adv
. 2019 Aug;
5(8):eaaw9906.
PMID: 31453333
Recent technological advancements in wearable sensors have made it easier to detect sweat components, but our limited understanding of sweat restricts its application. A critical bottleneck for temporal and regional...
9.
Vu V, Hangasky J, Detomasi T, Henry S, Ngo S, Span E, et al.
J Biol Chem
. 2019 Jun;
294(32):12157-12166.
PMID: 31235519
Degradation of polysaccharides is central to numerous biological and industrial processes. Starch-active polysaccharide monooxygenases (AA13 PMOs) oxidatively degrade starch and can potentially be used with industrial amylases to convert starch...
10.
Chaplin V, Hangasky J, Huang H, Duan R, Maroney M, Knapp M
Inorg Chem
. 2018 Sep;
57(20):12588-12595.
PMID: 30252455
α-Ketoglutarate (αKG) dependent oxygenases comprise a large superfamily of enzymes that activate O for varied reactions. While most of these enzymes contain a nonheme Fe bound by a His(Asp/Glu) facial...